WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2007002139) NEUROPROTECTION OF RETINAL GANGLION CELLS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/002139    International Application No.:    PCT/US2006/024063
Publication Date: 04.01.2007 International Filing Date: 21.06.2006
IPC:
A61K 39/395 (2006.01)
Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA [US/US]; 3160 CHESTNUT STREET, Suite 200, Philadelphia, PA 19104-6283 (US) (For All Designated States Except US).
LATIES, Alan [US/US]; (US) (For US Only).
MITCHELL, Claire [US/US]; (US) (For US Only)
Inventors: LATIES, Alan; (US).
MITCHELL, Claire; (US)
Agent: COHEN, Mark, S.; Pearl Cohen Zedek Latzer, LLP, 1500 Broadway, 12th Floor, New York, NY 10036 (US)
Priority Data:
60/692,657 22.06.2005 US
60/718,721 21.09.2005 US
Title (EN) NEUROPROTECTION OF RETINAL GANGLION CELLS
(FR) NEUROPROTECTION DE CELLULES GANGLIONNAIRES DE LA RETINE
Abstract: front page image
(EN)This invention relates to the neuroprotection of the optic nerve and the treatment of glaucoma, more specifically, the invention is directed to a method of preventing, inhibiting, decreasing incidence and suppressing death in ganglion cells by manipulating the P2X7 and A3 receptors on ganglion cells, by reducing levels of ATP released into the extracellular space of the retina and enhancing the conversion of released extracellular ATP into adenosine.
(FR)L'invention se rapporte à la neuroprotection du nerf optique et au traitement du glaucome et plus particulièrement à une méthode de prévention, d'inhibition, de diminution de l'incidence et de suppression de la mort de cellules ganglionnaires, ledit procédé consistant à manipuler les récepteurs P2X7 et A3 sur des cellules ganglionnaires, à réduire les taux d'ATP libérée dans l'espace extracellulaire de la rétine et à stimuler la transformation d'ATP extracellulaire libérée en adénosine.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)